20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Company News

Adorial, C4X Discovery deal

C4X acquired fellow drug discovery company Adorial in a cash and stock deal valued at L1.7 million ($2.4 million). Adorial will receive 1.5 million shares of C4X at 106p per share and L72,000 ($99,864) in...